| Literature DB >> 35349017 |
Maureen Maurer1, Rikki Mangrum2, Tandrea Hilliard-Boone3, Andrew Amolegbe4, Kristin L Carman5, Laura Forsythe5, Rachel Mosbacher5, Julie Kennedy Lesch5, Krista Woodward5.
Abstract
BACKGROUND: Engaging patients and other stakeholders as partners in research offers promise in improving the relevance and usefulness of research findings.Entities:
Keywords: comparative effectiveness research; patient and public involvement; patient and stakeholder engagement; patient-centered outcomes research
Mesh:
Year: 2022 PMID: 35349017 PMCID: PMC8993962 DOI: 10.1007/s11606-021-07104-w
Source DB: PubMed Journal: J Gen Intern Med ISSN: 0884-8734 Impact factor: 6.473
Sample description
| Studies ( | |
| Completion status | |
| Active | 39 (67%) |
| PCORI funding announcement type | |
| Broad (investigator-initiated applications for patient-centered comparative clinical effectiveness research aligned with priority areas) | 31 (53%) |
| Pragmatic (applications for pragmatic clinical trials, large simple trials, or large-scale observational studies) | 11 (19%) |
| Targeted (one-time opportunity applications on specific, high-impact topics selected in response to input from patients and other stakeholders) | 16 (28%) |
| PCORI priority content area | |
| Addressing disparities | 15 (26%) |
| Assessment of prevention, diagnosis and treatment options | 15 (26%) |
| Communication and dissemination research | 8 (14%) |
| Improving healthcare systems | 20 (34%) |
| Study design | |
| Experimental | 46 (79%) |
| Observational | 8 (14%) |
| Quasi-experimental | 4 (7%) |
| Researcher interviews ( | |
| Principal investigator alone | 28 (48%) |
| Principal investigator designee alone* | 7 (12%) |
| Principal investigator plus other team member | 23 (40%) |
| Partner interview participant roles ( | |
| Patient or caregiver | 21 (41%) |
| Patient advocates or members of health or patient advocacy organizations | 11 (21%) |
| Clinicians | 4 (8%) |
| Subject matter experts | 3 (6%) |
| Engagement specialists | 2 (4%) |
| Representatives of community-based organizations | 2 (4%) |
| Multiple roles | 8 (16%) |
*The principal investigator requested that the project director or co-investigator complete the interview on their behalf
Examples of partner influence showing how engagement was integral to all study activities
| Research questions and plans | • Co-developed the study in initial project phases • Collaborated with researchers to determine priorities and suitable research questions • Co-wrote proposal for project funding • Confirmed that the study was important, feasible, timely, or worthwhile |
| Study design | • Discussed iteratively potential designs and endpoints • Adapted study design to address challenges and obstacles prior or during implementation • Identified weaknesses in the proposed design and helped determine how to address them • Challenged the use of a randomized controlled trial study design because partners wanted all patients to receive the benefits of the intervention • Helped determine inclusion/exclusion criteria by suggesting expansion of age range, diagnostic criteria, or additional groups (e.g., rural) • Agreed with and validated aspects of the study design |
| Outcome and measurement approaches | • Disputed research team’s choices and proposed alternatives for study outcomes • Helped to prioritize among desirable outcomes to study • Identified gaps in available instruments and new or additional domains for inclusion • Developed new surveys or survey items • Advised on the content or phrasing of surveys or survey items • Tested candidate instruments • Evaluated the feasibility, usability, and burden of selected measures |
| Intervention design and implementation | • Influenced the content and format of intervention materials (e.g., videos, apps, websites) by adding or removing content, making language patient-friendly, or making materials easier to use in the field or doctor’s office • Adapted interventions to fit study sites, clinic workflow, or patient experience • Trained intervention providers • Led intervention activities |
| Recruitment and enrollment processes and materials | • Conducted outreach activities to sites and patients • Created flyers, letters, and informed consent materials • Advised and cautioned researchers how content, messaging, or language might be misinterpreted during recruitment • Edited materials to make them shorter and clearer and improve cultural appropriateness • Enrolled patients in the study |
| Retention approaches | • Conducted retention activities, such as follow-up phone calls • Developed strategies for encouraging retention • Suggested adding incentives to prevent attrition • Created or directed the creation of tools to engage study participants, such as a newsletter or a Facebook group |
| Data collection | • Conducted interviews • Provided technical assistance to study sites • Facilitated communication between sites and researchers |
| Data analysis | • Supplied context to explain study results • Offered alternate interpretations of study results • Suggested conducting additional analyses |
| Dissemination | • Brainstormed and planned for dissemination, including offering advice on vehicles • Created dissemination products, such as presentations or manuscripts • Participated in dissemination activities |
| Engagement | • Designed or led engagement • Developed or requested alternative engagement strategies • Created written guidance and tools to support engagement • Suggested and recruited new partners |
The dynamic influence of engagement on PCORI-funded research: definitions, examples, and frequency of types of influence by researcher and partner interview participants
| Redirecting: Partners shift the study’s direction or create new plans or materials | • Disputed research team’s choices and proposed alternatives for outcomes or measures • Recommended different recruitment strategies • Suggested new avenues for dissemination | 39 (67%) | 42 (82%) | 81 (74%) |
| Co-producing: Partners and researchers work together or collaborate | • Approached researchers with study idea • Developed the intervention for the study • Led study recruitment | 42 (72%) | 33 (65%) | 75 (69%) |
| Refining: Partners edit or modify existing plans or material | • Edited study materials or manuscripts • Suggested improvements to study implementation procedures | 47 (81%) | 24 (47%) | 71 (65%) |
| Limited or no influence: Researchers were unable to implement partner suggestions | • IRB constraints limited ability to implement suggestions • Researchers decided not to implement • Partners felt they did not have much to contribute | 20 (34%) | 16 (31%) | 36 (33%) |
| Confirming: Partners validate existing plans or materials | • Validated that study aims were important • Reviewed study recruitment materials | 8 (14%) | 4 (8%) | 12 (11%) |
Note: Types of influence listed in order of frequency of report (i.e., total number of researchers and partners who reported it)
Illustrative quotes for types of engagement influence and impact
|
| “People had problems with [blood samples being sent away for analysis]. They didn’t want to have their blood go out from their community. Based on the suggestion from …the advisory panel, we decided that we will work with the local health services where they will do the lab work.” (Researcher) |
|
| “From the very first glimmer, I was involved. We sketched out what a trial would look like together and wrote the grant together.” (Partner) |
|
| “We were missing eligible patients because of a [four-week screening] window. All these clinicians realized that and said, ‘let’s change the protocol.’ And we did make that window bigger.” (Researcher) |
|
| “We had an online platform that we wish we would have had a little more involvement with the development, because it was an issue with a lot of our patients using that platform.” (Partner) |
|
| “It was a complicated study. When we initially came up with the idea, we weren’t sure that it was even going to be feasible. But after again engaging the stakeholders…we were reassured and encouraged to move forward with it.” (Researcher) |
|
| “Another challenge [the researchers had was] making this questionnaire user-friendly, not asking too invasive questions … we gave them suggestions from a patient standpoint.” (Partner) |
|
| “The survey questionnaires were coming in at a slower pace than what the researchers wanted… [After we gave our suggestions], they realized a huge difference. They mentioned something like 80, 90 percent [up] from 50 percent.” (Partner) |
|
| “The stakeholders gave us insights and suggestions that we probably wouldn’t have come up with on our own that in the end improved the trial design, trial implementation, and, hopefully, will give us the most meaningful results.” (Researcher) |
|
| “We worked together and created a patient partner guide and a handbook and a glossary … It’s something that we will have to continue to refine and change to make it as user friendly as possible.” (Partner) |
|
| “We published an article that documented the results of our focus groups and key informant interviews with patients and caregivers, and through their [partners] assistance, we ended up getting an Altmetric score that placed us in the top 5% of all medical articles published….I attribute it to what they did.” (Researcher) |
How engagement shapes PCORI-funded studies: definitions, examples, and frequency of types of impact reported by researcher and partner interview participants
| Types | Examples | Frequency of report | ||
|---|---|---|---|---|
| Researcher, | Partner, | Total, | ||
| User-centeredness and acceptability: How well the study and study materials reflected the needs and preferences of patients, providers, or other partners | • Prioritized outcomes that matter to patients • Reduced burden for study site staff • Reflected user preferences for study implementation • Address lack of interest from patient populations or sites | 54 (93%) | 44(86%) | 98 (90%) |
| Study feasibility: How well the team was able to execute study activities in a timely, cost-effective way | • Improved ability to collect data • Improved recruitment process and materials • Changes to project management, such as increasing or decreasing costs | 41 (70%) | 32 (55%) | 73 (67%) |
| Study quality: Changes to quality of study design and study materials | • Improved study’s comprehensiveness • Changes to rigor of study design • Improved quality of intervention materials | 43 (74%) | 27 (53%) | 70 (64%) |
| Engagement scope and quality: How well the study engaged diverse stakeholders across study activities | • Improved representation by expanding the number or types of stakeholders involved • Improved engagement processes | 22 (38%) | 11 (21%) | 33 (30%) |
| Relevance: Usefulness of study results to intended audiences | • Validated that study aims and outcomes were important and meaningful • Increased receptivity of study findings | 10 (17%) | 2 (4%) | 12 (11%) |
Note: Types of impact listed in order of frequency of report (i.e., total number of researchers and partners who reported it)